Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-08-01

FDA Approved: ZARXIO — Supplemental Application (Sandoz Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Zarxio (filgrastim-sndz) submitted by Sandoz Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ZARXIO (FILGRASTIM-SNDZ)

Snippet

SUPPL AP for ZARXIO (FILGRASTIM-SNDZ)